Enhancement of serum and mucosal immune responses to a Haemophilus influenzae type B vaccine by intranasal delivery

Clinical and Vaccine Immunology

Volumn 20, Issue 11, 2013, Pages 1690-1696

  Fernandez, Stefan ^a   Cisney, Emily D ^a   Ulrich, Robert G ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE PLUS TETANUS TOXOID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; LYMPHOID TISSUE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; SALIVA; SERUM; VACCINES, CONJUGATE;

EID: 84886735504     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00215-13     Document Type: Article

References (52)

1. Oh SY, Griffiths D, John T, Lee YC, Yu LM, McCarthy N, Heath PT, Crook D, Ramsay M, Moxon ER, Pollard AJ. 2008. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J. Infect. Dis. 197:1275-1281.
2. Williams EJ, Lewis J, John T, Hoe JC, Yu L, Dongol S, Kelly DF, Griffiths DT, Shah A, Limbu B, Pradhan R, Mawas F, Shrestha S, Thorson S, Werno AM, Murdoch DR, Adhikari N, Pollard AJ. 2011. Haemophilus influenzae type b carriage and novel bacterial population structure among children in urban Kathmandu, Nepal. J. Clin. Microbiol. 49:1323-1330.
3. Fernandez J, Levine OS, Sanchez J, Balter S, LaClaire L, Feris J, Romero-Steiner S. 2000. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J. Infect. Dis. 182:1553-1556.
4. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team. 2009. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 374:903-911.
5. Siber GR, Anderson R, Habafy M, Gupta RK. 1995. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 13:525-531.
6. Stein KE. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165(Suppl 1):S49-S52.
7. Redhead K, Sesardic D, Yost SE, Attwell AM, Watkins J, Hoy CS, Plumb JE, Corbel MJ. 1994. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity. Biologicals 22:339-345.
8. Guttormsen HK, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. 1999. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67:6375-6384.
9. Rappuoli R, De Gregorio E. 2011. A sweet T cell response. Nat. Med. 17:1551-1552.
10. Avci FY, Li X, Tsuji M, Kasper DL. 2011. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17:1602-1609.
11. von Hunolstein C, Mariotti S, Teloni R, Alfarone G, Romagnoli G, Orefici G, Nisini R. 2001. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anticarrier polyvalent vaccines. Vaccine 19:3058-3066.
12. Kauppi-Korkeila M, Saarinen L, Eskola J, Kayhty H. 1998. Subclass distribution of IgA antibodies in saliva and serum after immunization with Haemophilus influenzae type b conjugate vaccines. Clin. Exp. Immunol. 111:237-242.
13. Fernandez S, Cisney ED, Hall SI, Ulrich RG. 2011. Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue. Clin. Vaccine Immunol. 18:667-675.
14. Debertin AS, Tschernig T, Tönjes H, Kleemann WJ, Tröger HD, Pabst R. 2003. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin. Exp. Immunol. 134:503-507.
15. Park HS, Francis KP, Yu J, Cleary PP. 2003. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J. Immunol. 171:2532-2537.
16. Zuercher AW, Horn MP, Wu H, Song Z, Bundgaard CJ, Johansen HK, Høiby N, Marcus P, Lang AB. 2006. Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine 24:4333-4342.
17. Hou Y, Hu WG, Hirano T, Gu XX. 2002. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine 20:2375-2381.
18. Sekine S, Kataoka K, Fukuyama Y, Adachi Y, Davydova J, Yamamoto M, Kobayashi R, Fujihashi K, Suzuki H, Curiel DT, Shizukuishi S, McGhee JR. 2008. A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J. Immunol. 180:8126-8134.
19. Zuercher AW, Coffin SE, Thurnheer MC, Fundova P, Cebra JJ. 2002. Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J. Immunol. 168:1796-1803.
20. Tyrer P, Foxwell AR, Cripps AW, Apicella MA, Kyd JM. 2006. Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect. Immun. 74:625-631.
21. Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J. 2000. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. Infect. Immun. 68:5749-5755.
22. Shen X, Lagergård T, Yang Y, Lindblad, Fredriksson M, Holmgren J. 2000. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 19:850-861.
23. Mariotti S, Teloni R, von Hunolstein C, Romagnoli G, Orefici G, Nisini R. 2002. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine 20:2229-2239.
24. Ugozzoli M, Mariani M, Del Giudice G, Soenawan E, O'Hagan DT. 2002. Combinations of protein polysaccharide conjugate vaccines for intranasal immunization. J. Infect. Dis. 186:1358-1361.
25. Zola TA, Lysenko ES, Weiser JN. 2009. Natural antibody to conserved targets of Haemophilus influenzae limits colonization of the murine nasopharynx. Infect. Immun. 77:3458-3465.
26. Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. 2007. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 14:1499-1504.
27. Stiles BG, Garza AR, Ulrich RG, Boles JW. 2001. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model. Infect. Immun. 69:2031-2036.
28. Schlesinger Y, Granoff DM. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267:1489-1494.
29. Romero-Steiner S, Fernandez J, Biltoft C, Wohl ME, Sanchez J, Feris J, Balter S, Levine OS, Carlone GM. 2001. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin. Diagn. Lab Immunol. 8:1115-1119.
30. Kauppi M, Saarinen L, Käyhty H. 1993. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats. J. Infect. Dis. 167:365-371.
31. Kauppi M, Eskola J, Käyhty H. 1995. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr. Infect. Dis. J. 14:286-294.
32. Kauppi-Korkeila M, van Alphen L, Madore D, Saarinen L, Käyhty H. 1996. Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. J. Infect. Dis. 174:1337-1340.
33. Breukels MA, Jol-van der Zijde E, van Tol MJ, Rijkers GT. 2002. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin. Infect. Dis. 34:191-197.
34. Lee YC, Kelly DF, Yu LM, Slack MP, Booy R, Heath PT, Siegrist CA, Moxon RE, Pollard AJ. 2008. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin. Infect. Dis. 46:186-192.
35. Kawashima H, Fukuda M. 2012. Sulfated glycans control lymphocyte homing. Ann. N. Y. Acad. Sci. 1253:112-121.
36. Brandtzaeg P, Farstad IN, Haraldsen G. 1999. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today 20:267-277.
37. Brandtzaeg P, Baekkevold ES, Farstad IN, Jahnsen FL, Johansen FE, Nilsen EM, Yamanaka T. 1999. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol. Today 20:141-151.
38. Kunkel EJ, Butcher EC. 2003. Plasma-cell homing. Nat. Rev. Immunol. 3:822-829.
39. Kataoka K, Fujihashi K, Terao Y, Gilbert RS, Sekine S, Kobayashi R, Fukuyama Y, Kawabata S. 2011. Oral-nasopharyngeal dendritic cells mediate T cell-independent IgA class switching on B-1 B cells. PLoS One 6:e25396. doi:10.1371/journal.pone.0025396.
40. Casteleyn C, Broos AM, Simoens P, Van den Broeck W. 2009. NALT (nasal cavity-associated lymphoid tissue) in the rabbit. Vet. Immunol. Immunopathol. 133:212-218.
41. Asanuma H, Thompson AH, Iwasaki T, Sato Y, Inaba Y, Aizawa C, Kurata T, Tamura S. 1997. Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods 202:123-131.
42. Fukuyama S, Nagatake T, Kim DY, Takamura K, Park EJ, Kaisho T, Tanaka N, Kurono Y, Kiyono H. 2006. Cutting edge: uniqueness of lymphoid chemokine requirement for the initiation and maturation of nasopharynx-associated lymphoid tissue organogenesis. J. Immunol. 177:4276-4280.
43. Rangel-Moreno J, Moyron-Quiroz J, Kusser K, Hartson L, Nakano H, Randall TD. 2005. Role of CXC chemokine ligand 13, CC chemokine ligand (CCL) 19, and CCL21 in the organization and function of nasal-associated lymphoid tissue. J. Immunol. 175:4904-4913.
44. Harmsen A, Kusser K, Hartson L, Tighe M, Sunshine MJ, Sedgwick JD, Choi Y, Littman DR, Randall TD. 2002. Cutting edge: organogenesis of nasal-associated lymphoid tissue (NALT) occurs independently of lymphotoxin-alpha (LT alpha) and retinoic acid receptor-related orphan receptor-gamma, but the organization of NALT is LT alpha dependent. J. Immunol. 168:986-990.
45. Kiyono H, Fukuyama S. 2004. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4:699-710.
46. Zuercher AW, Cebra JJ. 2002. Structural and functional differences between putative mucosal inductive sites of the rat. Eur. J. Immunol. 32:3191-3196.
47. Bienenstock J, McDermott MR. 2005. Bronchus- and nasal-associated lymphoid tissues. Immunol. Rev. 206:22-31.
48. Heritage PL, Underdown BJ, Arsenault AL, Sniden DP, McDermott MR. 1997. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am. J. Respir. Crit. Care Med. 156(4 Pt 1):1256-1262.
49. Lo DD, Ling J, Eckelhoefer AH. 2012. M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotechnol. 12:7. doi:10.1186/1472-6750-12-7.
50. Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K. 2008. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 26:4849-4859.
51. Kataoka K, Fujihashi K. 2009. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev. Vaccines 8:1183-1193.
52. Visweswaraiah A, Novotny LA, Hjemdahl-Monsen EJ, Bakaletz LO, Thanavala Y. 2002. Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention. Vaccine 20:3209-3220.